Quimigen Group Newsletter

Quimigen Group announces its plans for 2024, including the launch of the Oncotarget kit for the study of solid tumors, as well as advances in clinical studies of metastatic colorectal cancer. They also strengthen their market presence by partnering with Genexpath for sarcoma and lymphoma diagnostics, affirming their commitment to innovation and medical advancement.


Quimigen Group Newsletter


Quimigen unveils ambitious projects for 2024 in the fields of diagnostics and scientific research

Dear readers, 

We are delighted to share with you Quimigen' plans for 2024, demonstrating our ongoing commitment to research and diagnostics.

The first highlight of this year's roadmap is the launch of a new kit for the study of solid tumors using NGS technology: Oncotarget. This launch is the result of a fruitful collaboration with SATT SAYENS and the University of Burgundy, underlying both our desire to add value to academic research, and our constant drive to push back the frontiers of innovation in oncology.

In addition, we are proud to announce the imminent completion of a clinical study promoted by Limoges University Hospital for the Oncogramme® (CE/IVD), our functional diagnostic test for metastatic colorectal cancer.

This study represents a major milestone towards the launch of the Oncogramme® in routine diagnostics. In addition, the acceleration of patient enrolment in our other clinical trial, ONCOG1, sponsored by Oncomedics (a Group subsidiary) and conducted in collaboration with the Hôpital Saint Joseph in Marseille, illustrates our determination to bring this technology to all oncologists to guide them in the treatment of their patients with metastatic colorectal cancer.

Furthermore, in a move designed to strengthen our market presence, Quimigen has committed to taking part in the capital increase of Genexpath, a Rouen-based company offering CE/IVD-marked kits for the diagnosis of sarcoma (SarcomaFusion) and lymphoma (LymphoSign). This strategic collaboration underlines our commitment to diversifying our offerings, enabling us to better meet the ever-changing needs of oncology diagnostics.

Finally, Quimigen has positioned itself as a market-driven player, constantly seeking opportunities for commercial partnerships and investments in the fields of oncology, biomanufacturing and preclinical research. Our aim is to maintain a dynamic of constant innovation and to actively contribute to the advancement of medical sciences in all 15 European countries where we are present and where we strengthen our teams year after year.

Tushendan Rasiah

CEO  Quimigen Group



PHRCi clinical study  


Oncog clinical study as part of the "Forfait Innovation" 


This randomized clinical trial of Oncogramme® for Metastatic colorectal cancer (CRCm) is being conducted by the University Hospital of Limoges, and more specifically by Pr Mathonnet's department, in collaboration with Oncomedics, and with the participation of 13 French hospitals.

All 256 patients in this clinical study have been included since its launch in 2017. Follow-up information from the last patients included will be known next April, with publication of the final results expected by the end of 2024.

The treatments analyzed as part of the CRCm Oncogramme® are as follows: Folfirinox, Folfox, Folfiri and 5FU + Folinic Acid.

The objectives of this randomized trial are to study the impact of the CRCm Oncogramme® by comparing a group of patients with metastatic colorectal cancer (mCRC) whose chemotherapy treatment is adapted according to the results of the functional test and a group whose treatment follows the usual recommendations. The following criteria are studied:

  • Primary objective:

Progression-free survival at 1 year.

  • Secondary objectives:

Response to first-line treatment administered ;

Overall survival at 6 months and 1 year;

Specific survival at 6 months and 1 year;

Incremental cost/efficacy/utility ratio; Evolution of Quality of Life ;

Failure to adapt chemotherapy ;

Grade 3 and higher chemotherapy-related adverse events.








This randomized clinical trial is being promoted by Oncomedics and Hôpital Saint Joseph de Marseille, and more specifically Dr. Perrier's department, which is the counter-coordinator.

It follows Oncomedics' award of the Forfait Innovation in 2019, supported by the HAS (French health authority) and the French Ministry of Health.

The study aims to enroll 450 patients with metastatic colorectal cancer, and enrolment is currently underway.

In addition to chemotherapies or combinations of chemotherapies (Folfirinox, Folfox, Folfiri and 5FU + Folinic Acid), the treatments analyzed in this clinical trial include targeted therapies prescribed to treat metastatic colorectal cancer.

The primary completion date for this study is scheduled for the end of 2025, with an estimated final completion date of December 2026.

The objectives of this randomized two-arm study (treatment decision-making with or without Oncogramme®) are to study the impact of the CCRm Oncogram on the following items at 12 months:

  • Primary objective:

Progression-free survival.

  • Secondary objectives:

Objective response rate ;

Response time ;

Rate of treatment change due to tumor progression at 2 months ;

Number of patients with secondary resectability of metastases ;

Overall survival;

Diagnostic performance of Oncogramme;

Budgetary impact at 12 months;

Quality of life for patients

      Read more      
      Read more      



Following the signature in May 2023 of a licensing agreement with SATT Sayens and the University of Burgundy, for a genetic test on solid and liquid biopsies for orientation towards cancer therapies, Quimigen is delighted to announce the commercial launch of the Oncotarget kit.

The Oncotarget kit is an NGS sequencing panel designed to identify, rapidly and reliably, genetic mutations associated with several cancer pathologies from patient samples of various types, thus guiding practitioners in their decisions concerning the patient's cancer treatment. The Oncotarget panel is a combination of 1229 different probes, enabling the detection of mutations present in all the coding regions of 10 genes used to guide 1- and 2-line therapy of several metastatic solid cancers.